Research shows that blocking IL-17A enhances the effectiveness of anti-PD-1 therapy in MSS CRC mouse models, making it a viable therapeutic target to improve ICI treatment response in MSS CRC patients (Liu et al., 2021b). The gene discussed is IL17A; the disease is colorectal carcinoma.